

S/N 09/734,281

PATENTIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	MERCKEN ET AL.	Examiner:	P. DUFFY
Serial No.:	09/734,281	Group Art Unit:	1645
Filed:	DECEMBER 11, 2000	Docket No.:	12546.4USC1
Customer No.	23552		
Title:	MONOCLONAL ANTIBODIES DIRECTED AGAINST THE MICROTUBULE- ASSOCIATED PROTEIN TAU		

CERTIFICATE UNDER 37 CFR 1.6(d): I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on March 8, 2004.

By:

Rebecca Bortolotti

Name: Rebecca Bortolotti

TERMINAL DISCLAIMER TO OBVIATE
A DOUBLE PATENTING REJECTION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Petitioner, N.V. Innogenetics S.A., a corporation organized and existing under the laws of Belgium and having its primary place of business at Ghent, Belgium, represents that it is the owner of the entire right, title and interest in U.S. Patent Application Serial No. 09/734,281, filed on December 11, 2000 and entitled Monoclonal Antibodies Directed Against The Microtubule - Associated Protein Tau, by virtue of our assignment recorded at Reel 6959, Frame(s) 0521. Attached herewith is a Certificate under 37 C.F.R. § 3.73(b) establishing N.V. Innogenetics right as assignee to take action.

Petitioner, N.V. Innogenetics, hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the above-identified application, which would extend beyond the expiration date of the full statutory term of U.S. Patent No. 6,121,003 and

Please charge Deposit Account No. 13-2725 in the amount of \$110.00 to cover the required Terminal Disclaimer fee for a large entity.

Date:

8 March 2004

Rebecca A. Bortolotti

Attorney for Applicants
Rebecca A. Bortolotti
REG. No. 51,488